ライフサイエンスコーパス: hypertrophic cardiomyopathy

1 gulated in dilated cardiomyopathy but not in hypertrophic cardiomyopathy.

2 er phenotypes, including 1,078 patients with hypertrophic cardiomyopathy.

3 ice developed a cardiac phenotype similar to hypertrophic cardiomyopathy.

4 tonia, optic atrophy, axonal neuropathy, and hypertrophic cardiomyopathy.

5 f cardiac disease, such as arrhythmogenic or hypertrophic cardiomyopathy.

6 MI), patients undergoing septal ablation for hypertrophic cardiomyopathy.

7 eta-adrenergic signaling, heart failure, and hypertrophic cardiomyopathy.

8 f MF in 30 transplanted hearts of end-stage, hypertrophic cardiomyopathy.

9 s support a cumulative variant hypothesis in hypertrophic cardiomyopathy.

10 lcohol septal ablation (ASA) in patient with hypertrophic cardiomyopathy.

11 Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy.

12 red with suspicion of genetically determined hypertrophic cardiomyopathy.

13 On autopsy, a patient is found to have hypertrophic cardiomyopathy.

14 ides prognostic information in patients with hypertrophic cardiomyopathy.

15 ar hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy.

16 ions, like mice with similar mutations, have hypertrophic cardiomyopathy.

17 med in 558 consecutive proband patients with hypertrophic cardiomyopathy.

18 ts had a structurally normal heart and 3 had hypertrophic cardiomyopathy.

19 providing a preclinical marker of disease in hypertrophic cardiomyopathy.

20 nted with lactic acidosis and nine developed hypertrophic cardiomyopathy.

21 ondrial disease patient who died of neonatal hypertrophic cardiomyopathy.

22 outcomes in a large cohort of patients with hypertrophic cardiomyopathy.

23 n genes coding for sarcomeric proteins cause hypertrophic cardiomyopathy.

24 ely to be a highly penetrant variant causing hypertrophic cardiomyopathy.

25 3 criteria identified 98.1% of athletes with hypertrophic cardiomyopathy.

26 lied to 4297 WAs and 103 young athletes with hypertrophic cardiomyopathy.

27 peptide (BNP) and survival in patients with hypertrophic cardiomyopathy.

28 s associated with worse clinical outcomes in hypertrophic cardiomyopathy.

29 rmalities and tissue injury in patients with hypertrophic cardiomyopathy.

30 ere mutation carriers at risk for developing hypertrophic cardiomyopathy.

31 nd tissue injury are common in patients with hypertrophic cardiomyopathy.

32 between DE on CMR and myocardial ischemia in hypertrophic cardiomyopathy.

33 t of routine evaluation of all patients with hypertrophic cardiomyopathy.

34 anxiety-like behavior in an animal model of hypertrophic cardiomyopathy.

35 in successfully prevented the development of hypertrophic cardiomyopathy.

36 bstitution in Sco1, which in humans causes a hypertrophic cardiomyopathy.

37 ostic value of GLS and LAVI in patients with hypertrophic cardiomyopathy.

38 nical management and genetic architecture of hypertrophic cardiomyopathy.

39 duced MEE at the early and advanced stage of hypertrophic cardiomyopathy.

40 nt of Fabry disease mimicking nonobstructive hypertrophic cardiomyopathy.

41 ng improves exercise capacity in adults with hypertrophic cardiomyopathy.

42 achycardia, congenital long QT syndrome, and hypertrophic cardiomyopathy.

43 ficiency causes Danon's disease, an X-linked hypertrophic cardiomyopathy.

44 me (31%), coronary artery disease (22%), and hypertrophic cardiomyopathy (14%).

45 ndromes (5), dilated cardiomyopathy (2), and hypertrophic cardiomyopathy (2).

46 d in families with long-QT syndrome (47%) or hypertrophic cardiomyopathy (46%).

47 ears; P<0.001), and have a family history of hypertrophic cardiomyopathy (53% versus 20%; P<0.001), a

48 n), 67 patients with a clinical diagnosis of hypertrophic cardiomyopathy (53+/-15 years, 76% men; 31

49 pertension (-4); positive family history for hypertrophic cardiomyopathy (6); morphology category (5)

50 diography was performed in 427 patients with hypertrophic cardiomyopathy (66% men, age 52+/-15 years)

51 e was established in 44.5% of athletes, with hypertrophic cardiomyopathy (81%) the most common pathol

52 Hypertrophic cardiomyopathy (9 [53%]) and respiratory in

53 ients undergoing septal alcohol ablation for hypertrophic cardiomyopathy, a human model of planned my

54 In hypertrophic cardiomyopathy, advanced HF not associated

55 We analyzed 531 patients with hypertrophic cardiomyopathy (age: 56+/-14 years, men 55%

56 Hypertrophic cardiomyopathy alone affects approximately

57 fficiency represents a target for therapy in hypertrophic cardiomyopathy although therapeutic benefit

58 The clinical course of patients with hypertrophic cardiomyopathy and advanced heart failure (

59 ry hypertension in patients with obstructive hypertrophic cardiomyopathy and advanced heart failure.

60 vein (PV) antrum isolation in patients with hypertrophic cardiomyopathy and atrial fibrillation (AF)

61 disease characterized by neurodegeneration, hypertrophic cardiomyopathy and diabetes.

62 ducible hypoperfusion is a common finding in hypertrophic cardiomyopathy and is typically identified

63 In patients with hypertrophic cardiomyopathy and left ventricular outflow

64 ciated with adverse outcome in patients with hypertrophic cardiomyopathy and may help to optimize ris

65 tions reflect the complex pathophysiology of hypertrophic cardiomyopathy and may provide clues for th

66 tive athletes, two deaths were attributed to hypertrophic cardiomyopathy and none to arrhythmogenic r

67 sitivity of the myofilaments is increased in hypertrophic cardiomyopathy and other heart diseases and

68 d RagB (RagA/B) in cardiomyocytes results in hypertrophic cardiomyopathy and phenocopies lysosomal st

69 variety of clinical manifestations including hypertrophic cardiomyopathy and renal insufficiency.

70 R21C (cTnI-R21C) mutation has been linked to hypertrophic cardiomyopathy and renders cTnI incapable o

71 e and are told that they are not at risk for hypertrophic cardiomyopathy and sudden cardiac death, an

72 at have previously been considered causal in hypertrophic cardiomyopathy and that are overrepresented

73 conversions associated with fatal infantile hypertrophic cardiomyopathy and the neurological disorde

74 ified a dose-dependent induction of dilated, hypertrophic cardiomyopathy, and arrhythmia inducibility

75 lic dysfunction, predisposing gene variants, hypertrophic cardiomyopathy, and congenital heart diseas

76 iles for healthy subjects, long QT syndrome, hypertrophic cardiomyopathy, and dilated cardiomyopathy

77 henotypes were verified in long QT syndrome, hypertrophic cardiomyopathy, and dilated cardiomyopathy

78 inergic polymorphic ventricular tachycardia, hypertrophic cardiomyopathy, and other hereditary cardia

79 nted in childhood with failure to thrive and hypertrophic cardiomyopathy, and the other was an adult

80 vity are consistent with the hypothesis that hypertrophic cardiomyopathies are hypersensitive to Ca(2

81 Dilated and hypertrophic cardiomyopathies are the most common; restr

82 Double mutations in patients with hypertrophic cardiomyopathy are much less common than pr

83 gests that double mutations in patients with hypertrophic cardiomyopathy are not rare and are associa

84 r predicting adverse events in patients with hypertrophic cardiomyopathy are still limited.

85 There was 1 case each (3%) of hypertrophic cardiomyopathy, arrhythmogenic right ventri

86 nder fasting conditions.Sirt5KO mice develop hypertrophic cardiomyopathy, as evident from the increas

87 importance of this finding in patients with hypertrophic cardiomyopathy, as well as the long-term sa

88 Two hypertrophic cardiomyopathy-associated cardiac troponin

89 The hypertrophic cardiomyopathy-associated mutant D145E, in

90 8V proband diagnosed with severe obstructive hypertrophic cardiomyopathy at 34 years of age exhibited

91 children who were diagnosed with idiopathic hypertrophic cardiomyopathy at age 1 year or older, with

92 For children diagnosed with hypertrophic cardiomyopathy at younger than 1 year, the

93 sidase A gene variants are misinterpreted as hypertrophic cardiomyopathy because of the lack of extra

94 In this large cohort of patients with hypertrophic cardiomyopathy, BNP was an independent pred

95 n thin-filament proteins have been linked to hypertrophic cardiomyopathy, but it has never been demon

96 wn to halt or reverse disease progression in hypertrophic cardiomyopathy, but the results of several

97 4R has previously been linked to dilated and hypertrophic cardiomyopathy, but was also found in healt

98 ure of cardiomyopathies, with an emphasis on hypertrophic cardiomyopathy caused by sarcomeric mutatio

99 -helix bundle that are associated with human hypertrophic cardiomyopathy caused either loss-of-functi

100 is, we first investigated the impact of five hypertrophic cardiomyopathy-causing (N1327K, E1356K, R13

101 ce in SHaRe most frequently occurred because hypertrophic cardiomyopathy centers had access to differ

102 Discordance in variant classification among hypertrophic cardiomyopathy centers is largely attributa

103 ment may be achieved by: 1) confining ASA to hypertrophic cardiomyopathy centers of excellence with h

104 rophic cardiomyopathy probands at 5 tertiary hypertrophic cardiomyopathy centers.

105 ate tool to predict a positive genotype in a hypertrophic cardiomyopathy cohort at a tertiary referra

106 ted to outflow obstruction (7% of the entire hypertrophic cardiomyopathy cohort) followed up for 6.1+

107 in genes associated with the pathogenesis of hypertrophic cardiomyopathy, dilated cardiomyopathy, and

108 iotensin II receptor blockers in preclinical hypertrophic cardiomyopathy-eg, in genotype-positive but

109 heart transplantation (HT) in patients with hypertrophic cardiomyopathy evaluated at 2 Italian refer

110 d >3 times and accounted for 78 of 185 (42%) hypertrophic cardiomyopathy families with a causal varia

111 CMR may be a useful adjunct in hypertrophic cardiomyopathy family screening, particular

112 Moreover, MR is key in differentiating HCM hypertrophic cardiomyopathy from "phenocopies"-that is,

113 ted longitudinal data for 1085 children with hypertrophic cardiomyopathy from 1990 to 2009.

114 ic cardiomyopathy who had undergone targeted hypertrophic cardiomyopathy genetic testing (either mult

115 ummed for each patient to create the Toronto hypertrophic cardiomyopathy genotype score.

116 more than a decade, risk stratification for hypertrophic cardiomyopathy has been enhanced by targete

117 Now, after more than 50 years, hypertrophic cardiomyopathy has been transformed from a

118 Genotyping in hypertrophic cardiomyopathy has gained increasing attent

119 t of drug-refractory symptoms of obstructive hypertrophic cardiomyopathy has long been debated and is

120 Infants with hypertrophic cardiomyopathy have a 2-year mortality of 3

121 alcohol septal ablation (ASA) in obstructive hypertrophic cardiomyopathy have been limited to small,

122 Hypertrophic cardiomyopathy ( HCM hypertrophic cardiomyo

123 ventricular cardiomyopathy (ARVC) (13%); and hypertrophic cardiomyopathy (HCM) (6%).

124 Myocardial fibrosis is a hallmark of hypertrophic cardiomyopathy (HCM) and a potential substr

125 wall thickening, and apply the technique in hypertrophic cardiomyopathy (HCM) and DCM.

126 in clinical practice, in particular, between hypertrophic cardiomyopathy (HCM) and increased LV wall

127 Angina is common in hypertrophic cardiomyopathy (HCM) and is associated with

128 verely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM) and mild septal hypert

129 pathogenic mutations in the TNT1 region, six hypertrophic cardiomyopathy (HCM) and two dilated cardio

130 The 2 most commonly affected genes in hypertrophic cardiomyopathy (HCM) are MYH7 (beta-myosin

131 Heterozygous mutations in sarcomere genes in hypertrophic cardiomyopathy (HCM) are proposed to exert

132 tain clinical and genetic characteristics of hypertrophic cardiomyopathy (HCM) at the population leve

133 tein C) founder mutations account for 35% of hypertrophic cardiomyopathy (HCM) cases in the Netherlan

134 terations in autophagy have been reported in hypertrophic cardiomyopathy (HCM) caused by Danon diseas

135 rizes the stereotypic phenotype proposed for hypertrophic cardiomyopathy (HCM) caused by thin-filamen

136 notypic and clinical course in a multicenter hypertrophic cardiomyopathy (HCM) cohort.

137 eft ventricular obstruction in patients with hypertrophic cardiomyopathy (HCM) during exercise echoca

138 The features of the hypertrophic cardiomyopathy (HCM) ECG make it a challeng

139 graphic data for automated discrimination of hypertrophic cardiomyopathy (HCM) from physiological hyp

140 Hypertrophic cardiomyopathy (HCM) has been prominently a

141 Hypertrophic cardiomyopathy (HCM) is a clinically and ge

142 Hypertrophic cardiomyopathy (HCM) is a common genetic di

143 Hypertrophic cardiomyopathy (HCM) is a common inherited

144 Hypertrophic cardiomyopathy (HCM) is a genetic disorder

145 Familial hypertrophic cardiomyopathy (HCM) is a prevalent heredit

146 RATIONALE: Hypertrophic cardiomyopathy (HCM) is a prototypic single

147 Hypertrophic cardiomyopathy (HCM) is a relatively common

148 Hypertrophic cardiomyopathy (HCM) is an important geneti

149 Hypertrophic cardiomyopathy (HCM) is an inherited diseas

150 Approximately 40% of hypertrophic cardiomyopathy (HCM) is caused by heterozyg

151 Hypertrophic cardiomyopathy (HCM) is caused by mutations

152 Hypertrophic cardiomyopathy (HCM) is caused by mutations

153 The natural history of hypertrophic cardiomyopathy (HCM) is complex and may inc

154 Yield of causative variants in hypertrophic cardiomyopathy (HCM) is increased in some p

155 Hypertrophic cardiomyopathy (HCM) is one of the most com

156 Hypertrophic cardiomyopathy (HCM) is the most common cau

157 Hypertrophic cardiomyopathy (HCM) is the most common inh

158 Hypertrophic cardiomyopathy (HCM) is the most common inh

159 The first mutation associated with hypertrophic cardiomyopathy (HCM) is the R403Q mutation

160 mplete penetrance and variable expression of hypertrophic cardiomyopathy (HCM) is well appreciated.

161 specific clinical red flags in patients with hypertrophic cardiomyopathy (HCM) older than 25 years.

162 ibuted to structural heart diseases, such as hypertrophic cardiomyopathy (HCM) or cardiac channelopat

163 hich they represent prephenotypic markers of hypertrophic cardiomyopathy (HCM) or incidental structur

164 A previously under-recognized subset of hypertrophic cardiomyopathy (HCM) patients with left ven

165 ere differentially expressed in the blood of hypertrophic cardiomyopathy (HCM) patients, and whether

166 general to all idiopathic dilated (IDCM) and hypertrophic cardiomyopathy (HCM) patients.

167 of a phosphorylation-mediated reversal of a hypertrophic cardiomyopathy (HCM) phenotype is novel.

168 h genetic mutations that are associated with hypertrophic cardiomyopathy (HCM) remains challenging.

169 Hypertrophic cardiomyopathy (HCM) results from mutations

170 European Society of Cardiology guidelines of hypertrophic cardiomyopathy (HCM) use a new clinical ris

171 with severe heart failure due to obstructive hypertrophic cardiomyopathy (HCM) who are at unacceptabl

172 The phenotype of individuals with hypertrophic cardiomyopathy (HCM) who exercise regularly

173 5% for dilated cardiomyopathy (DCM), 6% for hypertrophic cardiomyopathy (HCM), 12% for restrictive c

174 utation cTnI-R145G, which is associated with hypertrophic cardiomyopathy (HCM), a disease associated

175 c myosin heavy chain gene (MYH7) can lead to hypertrophic cardiomyopathy (HCM), a heritable disease c

176 In hypertrophic cardiomyopathy (HCM), accumulation of myoca

177 ted cardiomyopathy (NIDCM), 20 patients with hypertrophic cardiomyopathy (HCM), and 20 control health

178 for treatment of long QT-3 syndrome (LQT-3), hypertrophic cardiomyopathy (HCM), and ventricular tachy

179 ng vasodilator stress in patients with overt hypertrophic cardiomyopathy (HCM), as well as in HCM mut

180 In hypertrophic cardiomyopathy (HCM), heart transplant has

181 In hypertrophic cardiomyopathy (HCM), heterogeneous myocard

182 enetically heterogeneous conditions, such as hypertrophic cardiomyopathy (HCM), in which a considerab

183 AF), the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM), is capable of produci

184 the time of greatest risk for patients with hypertrophic cardiomyopathy (HCM), largely because of th

185 omeric mutation, which is exhibited in human hypertrophic cardiomyopathy (HCM), to investigate the in

186 ns, such as dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), which are often due t

187 (cMyBP-C), are the two most common causes of hypertrophic cardiomyopathy (HCM).

188 in an important proportion of patients with hypertrophic cardiomyopathy (HCM).

189 veral mutations in hVELC are associated with hypertrophic cardiomyopathy (HCM).

190 s into the cause of early SAM in obstructive hypertrophic cardiomyopathy (HCM).

191 ied filamin C (FLNC) as a candidate gene for hypertrophic cardiomyopathy (HCM).

192 to identify regulatory events that occur in hypertrophic cardiomyopathy (HCM).

193 tors (ICDs) in children and adolescents with hypertrophic cardiomyopathy (HCM).

194 ) hypertrophy (LVH) are cardinal features of hypertrophic cardiomyopathy (HCM).

195 young carriers of mutations associated with hypertrophic cardiomyopathy (HCM).

196 ute to arrhythmias and adverse remodeling in hypertrophic cardiomyopathy (HCM).

197 pathic left ventricular hypertrophy/possible hypertrophic cardiomyopathy (HCM; 3, 8%).

198 this case the two major clinical phenotypes (hypertrophic cardiomyopathy, HCM and dilated cardiomyopa

199 imaging in relation to the complexity of HCM hypertrophic cardiomyopathy , highlighting its role in c

200 Chronic or low-dose exposure may lead to hypertrophic cardiomyopathy; however, only acute exposur

201 We studied 121 patients with hypertrophic cardiomyopathy hypertrophic cardiomyopathy

202 post-mortem diagnosis; the most common were hypertrophic cardiomyopathy in 21 and congenital coronar

203 lts, clinicians routinely assess the risk of hypertrophic cardiomyopathy in a patient's relatives and

204 with abnormal ECG and with 1 case of apical hypertrophic cardiomyopathy in heterozygous females.

205 However, the mechanism leading to hypertrophic cardiomyopathy in heterozygous MYBPC3(+/-)

206 rn pathological and clinical descriptions of hypertrophic cardiomyopathy in the 1950s, which focused

207 e of multiple rare variants in patients with hypertrophic cardiomyopathy in the setting of comprehens

208 -month follow-up, 2 subjects developed overt hypertrophic cardiomyopathy, including 1 with mild LVH b

209 Sarcomere protein mutations in hypertrophic cardiomyopathy induce subtle cardiac struct

210 atients followed at the Tufts Medical Center Hypertrophic Cardiomyopathy Institute for 4.8+/-3.4 year

211 used for other indications in patients with hypertrophic cardiomyopathy, irrespective of obstructive

212 Hypertrophic cardiomyopathy is a common cause of mortali

213 Hypertrophic cardiomyopathy is a genetic disorder charac

214 Hypertrophic cardiomyopathy is a genetically heterogeneo

215 HCM hypertrophic cardiomyopathy is a multifaceted disease wi

216 Hypertrophic cardiomyopathy is associated with sudden ca

217 g exercise recommendations for patients with hypertrophic cardiomyopathy is challenging because of co

218 PV isolation in patients with hypertrophic cardiomyopathy is feasible and safe, althou

219 tricular tachycardia (NSVT) in patients with hypertrophic cardiomyopathy is incompletely resolved.

220 Hypertrophic cardiomyopathy is infrequently seen, and co

221 for additional genes that are implicated in hypertrophic cardiomyopathy is initiated on an affected

222 Hypertrophic cardiomyopathy is the most common type of c

223 Although hypertrophic cardiomyopathy is the most frequent cause o

224 The most common single genetic cause of hypertrophic cardiomyopathy is the recurrent MYBPC3 (myo

225 antage offered by CMR for early diagnosis of hypertrophic cardiomyopathy is unclear.

226 cardial strain are reported in patients with hypertrophic cardiomyopathy, ischemic heart disease, dia

227 n binding protein-C or titin, cause familial hypertrophic cardiomyopathies, it is important to determ

228 of myocardial perfusion; characterization of hypertrophic cardiomyopathy, left ventricular noncompact

229 ercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) trial, the lar

230 KI mice, whereas A399S-PKI mice expressing a hypertrophic cardiomyopathy-linked JPH2 mutation not ass

231 sis light chain [AL] type), 40 patients with hypertrophic cardiomyopathy matched for demographics and

232 ND One-hundred and ninety-five patients with hypertrophic cardiomyopathy (median age, 52.8+/-15.1 yea

233 Treatment of children with hypertrophic cardiomyopathy might be improved if the ris

234 Hypertrophic cardiomyopathy mitral malformations have be

235 is preliminary study involving patients with hypertrophic cardiomyopathy, moderate-intensity exercise

236 The human hypertrophic cardiomyopathy mutation R453C results in on

237 ular cardiomyopathy (n = 111), DCM (n = 95), hypertrophic cardiomyopathy (n = 40) and peripartum card

238 2), occult myocardial infarction (n=13), and hypertrophic cardiomyopathy (n=9) were most frequent.

239 ng abnormality and thus shares features with hypertrophic cardiomyopathies observed in the congenital

240 diac death (SCD) in athletes is debated with hypertrophic cardiomyopathy often reported as the most c

241 e underlying sarcomere hypercontractility of hypertrophic cardiomyopathy, one of the most prevalent h

242 ated in hypertrophic hearts of patients with hypertrophic cardiomyopathy or aortic stenosis.

243 sis when experiencing aortic valve stenosis, hypertrophic cardiomyopathy, or heart failure.

244 Hypertrophic cardiomyopathy patients (n=47) underwent CM

245 iameter, volume, and strain to risk stratify hypertrophic cardiomyopathy patients for new-onset atria

246 preferred methods to relieve obstruction in hypertrophic cardiomyopathy patients still symptomatic a

247 Screening 203 unrelated hypertrophic cardiomyopathy patients uncovered a novel J

248 A second cohort of 20 hypertrophic cardiomyopathy patients undergoing alcohol

249 Symptomatic adult hypertrophic cardiomyopathy patients undergoing surgery

250 dictors of long-term outcomes of symptomatic hypertrophic cardiomyopathy patients undergoing surgical

251 In end-stage, hypertrophic cardiomyopathy patients undergoing transpla

252 METHODS AND Clinical data of all hypertrophic cardiomyopathy patients with 2 rare genetic

253 onary hypertension was common in obstructive hypertrophic cardiomyopathy patients with advanced heart

254 of measured cardiopulmonary hemodynamics in hypertrophic cardiomyopathy patients with heart failure,

255 ith similar EF in 20 control subjects and 20 hypertrophic cardiomyopathy patients with increased wall

256 op of LA diameter to predict new-onset AF in hypertrophic cardiomyopathy patients with LA diameter <4

257 METHODS AND A total of 242 hypertrophic cardiomyopathy patients without AF history

258 In hypertrophic cardiomyopathy patients without significant

259 e diagnosis and prognostic assessment of HCM hypertrophic cardiomyopathy patients, as well as screeni

260 nd ischemia are not the sole causes of DE in hypertrophic cardiomyopathy patients.

261 me, and strain all relate to new-onset AF in hypertrophic cardiomyopathy patients.

262 an with detailed characterization of the HCM hypertrophic cardiomyopathy phenotype and assessment of

263 The subclinical hypertrophic cardiomyopathy phenotype measured by cardio

264 We tested this hypothesis in genetic hypertrophic cardiomyopathy pre-LVH (genotype positive,

265 g was performed on 358 consecutive genotyped hypertrophic cardiomyopathy probands at 5 tertiary hyper

266 METHODS AND Of 758 hypertrophic cardiomyopathy probands, we included 382 wi

267 Icelandic patients clinically diagnosed with hypertrophic cardiomyopathy resulted in identification o

268 itral regurgitation, prior valvular surgery, hypertrophic cardiomyopathy, rheumatic valvular disease,

269 thmias, supporting the importance of NSVT in hypertrophic cardiomyopathy risk stratification.

270 risk prediction model for SCD (HCM Risk-SCD [hypertrophic cardiomyopathy risk-SCD]).

271 one of several preclinical abnormalities in hypertrophic cardiomyopathy sarcomere gene mutation carr

272 actors for poor outcomes varied according to hypertrophic cardiomyopathy subgroup, but they generally

273 For all hypertrophic cardiomyopathy subgroups, the risk of death

274 rmine whether TNNC1 can be categorized as an hypertrophic cardiomyopathy susceptibility gene, such th

275 markedly lower among centers specialized in hypertrophic cardiomyopathy than among clinical laborato

276 Hypertrophic cardiomyopathy ( HCM hypertrophic cardiomyopathy ), the most common genetical

277 ation (ASA) for the treatment of obstructive hypertrophic cardiomyopathy, the arrhythmogenicity of th

278 l fibrosis (MF) has clinical implications in hypertrophic cardiomyopathy, the extent, type, and distr

279 In children with hypertrophic cardiomyopathy, the risk of death or heart

280 magnetic resonance parameters in subclinical hypertrophic cardiomyopathy to determine their strength

281 ercise testing is performed in patients with hypertrophic cardiomyopathy to evaluate blood pressure r

282 -15 years, range 16-86 years; 67% male) with hypertrophic cardiomyopathy underwent cardiopulmonary ex

283 One hundred consecutive patients with hypertrophic cardiomyopathy underwent cardiovascular mag

284 thogenic sarcomere mutation in patients with hypertrophic cardiomyopathy was associated with an incre

285 d clinical trial involving 136 patients with hypertrophic cardiomyopathy was conducted between April

286 No evidence of hypertrophic cardiomyopathy was found in either person.

287 ath in 16 (25%), and definitive evidence for hypertrophic cardiomyopathy was seen in 5 (8%).

288 l hypertrophy, traditionally associated with hypertrophic cardiomyopathy, was the commonest pattern o

289 mogenic right ventricular cardiomyopathy and hypertrophic cardiomyopathy were 4.2 to 6.7/100 patient-

290 genic (LP/P; >/=2) variants in patients with hypertrophic cardiomyopathy were described 10 years ago

291 ents from apparently unrelated families with hypertrophic cardiomyopathy were evaluated.

292 Patients with prior MV operation and apical hypertrophic cardiomyopathy were excluded.

293 d older) with obstructive or non-obstructive hypertrophic cardiomyopathy were randomly assigned via c

294 ferences between MYH7- and MYBPC3-associated hypertrophic cardiomyopathy when assessed by cardiac mag

295 METHODS AND Forty-one patients with hypertrophic cardiomyopathy who had undergone targeted h

296 10 (20%) heterozygous family members showed hypertrophic cardiomyopathy with an atypical distributio

297 were recorded for the 69 children with pure hypertrophic cardiomyopathy with inborn errors of metabo

298 cardiac magnetic resonance imaging revealed hypertrophic cardiomyopathy with left ventricular dysfun

299 mily with 3 males affected by nonobstructive hypertrophic cardiomyopathy with severe left ventricular

300 We studied 699 consecutive patients who have hypertrophic cardiomyopathy with severe symptomatic left